File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effect of paricalcitol on left ventricular mass and function in CKD-The OPERA trial

TitleEffect of paricalcitol on left ventricular mass and function in CKD-The OPERA trial
Authors
Issue Date2014
Citation
Journal of the American Society of Nephrology, 2014, v. 25, n. 1, p. 175-186 How to Cite?
AbstractVitamin D seems to protect against cardiovascular disease, but the reported effects of vitaminDon patient outcomes in CKD are controversial. We conducted a prospective, double blind, randomized, placebocontrolled trial to determine whether oral activated vitamin D reduces left ventricular (LV)mass in patients with stages 3-5 CKD with LV hypertrophy. Subjects with echocardiographic criteria of LV hypertrophy were randomly assigned to receive either oral paricalcitol (1 μg) one time daily (n=30) ormatching placebo (n=30) for 52 weeks. The primary end point was change in LV mass index over 52 weeks, which was measured by cardiac magnetic resonance imaging. Secondary end points included changes in LV volume, echocardiographic measures of systolic and diastolic function, biochemical parameters of mineral bone disease, and measures of renal function. Change in LV mass index did not differ significantly between groups (median [interquartile range], 22.59 [26.13 to 0.32] g/m2 with paricalcitol versus 24.85 [29.89 to 1.10] g/m2 with placebo). Changes in LV volume, ejection fraction, tissue Doppler-derived measures of early diastolic and systolicmitral annular velocities, and ratio of earlymitral inflowvelocity to early diastolic mitral annular velocity did not differ between the groups. However, paricalcitol treatment significantly reduced intact parathyroid hormone (P,0.001) and alkaline phosphatase (P=0.001) levels as well as the number of cardiovascular-related hospitalizations compared with placebo. In conclusion, 52 weeks of treatment with oral paricalcitol (1 mg one time daily) significantly improved secondary hyperparathyroidism but did not alter measures of LV structure and function in patients with severe CKD. Copyright © 2014 by the American Society of Nephrology.
Persistent Identifierhttp://hdl.handle.net/10722/228477
ISSN
2015 Impact Factor: 8.491
2015 SCImago Journal Rankings: 4.699

 

DC FieldValueLanguage
dc.contributor.authorWang, Angela Yee Moon-
dc.contributor.authorFang, Fang-
dc.contributor.authorChan, John-
dc.contributor.authorWen, Yue Yi-
dc.contributor.authorQing, Shang-
dc.contributor.authorChan, Iris Hiu Shuen-
dc.contributor.authorLo, Gladys-
dc.contributor.authorLai, Kar Neng-
dc.contributor.authorLo, Wai Kei-
dc.contributor.authorLam, Christopher Wai Kei-
dc.contributor.authorYu, Cheuk Man-
dc.date.accessioned2016-08-13T08:02:30Z-
dc.date.available2016-08-13T08:02:30Z-
dc.date.issued2014-
dc.identifier.citationJournal of the American Society of Nephrology, 2014, v. 25, n. 1, p. 175-186-
dc.identifier.issn1046-6673-
dc.identifier.urihttp://hdl.handle.net/10722/228477-
dc.description.abstractVitamin D seems to protect against cardiovascular disease, but the reported effects of vitaminDon patient outcomes in CKD are controversial. We conducted a prospective, double blind, randomized, placebocontrolled trial to determine whether oral activated vitamin D reduces left ventricular (LV)mass in patients with stages 3-5 CKD with LV hypertrophy. Subjects with echocardiographic criteria of LV hypertrophy were randomly assigned to receive either oral paricalcitol (1 μg) one time daily (n=30) ormatching placebo (n=30) for 52 weeks. The primary end point was change in LV mass index over 52 weeks, which was measured by cardiac magnetic resonance imaging. Secondary end points included changes in LV volume, echocardiographic measures of systolic and diastolic function, biochemical parameters of mineral bone disease, and measures of renal function. Change in LV mass index did not differ significantly between groups (median [interquartile range], 22.59 [26.13 to 0.32] g/m2 with paricalcitol versus 24.85 [29.89 to 1.10] g/m2 with placebo). Changes in LV volume, ejection fraction, tissue Doppler-derived measures of early diastolic and systolicmitral annular velocities, and ratio of earlymitral inflowvelocity to early diastolic mitral annular velocity did not differ between the groups. However, paricalcitol treatment significantly reduced intact parathyroid hormone (P,0.001) and alkaline phosphatase (P=0.001) levels as well as the number of cardiovascular-related hospitalizations compared with placebo. In conclusion, 52 weeks of treatment with oral paricalcitol (1 mg one time daily) significantly improved secondary hyperparathyroidism but did not alter measures of LV structure and function in patients with severe CKD. Copyright © 2014 by the American Society of Nephrology.-
dc.languageeng-
dc.relation.ispartofJournal of the American Society of Nephrology-
dc.titleEffect of paricalcitol on left ventricular mass and function in CKD-The OPERA trial-
dc.typeArticle-
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.1681/ASN.2013010103-
dc.identifier.scopuseid_2-s2.0-84891774529-
dc.identifier.volume25-
dc.identifier.issue1-
dc.identifier.spage175-
dc.identifier.epage186-
dc.identifier.eissn1533-3450-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats